Nanobiotix (NBTX) News Today $3.24 -0.14 (-4.14%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call TranscriptApril 3 at 5:01 PM | seekingalpha.comNANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial ResultsApril 2 at 4:15 PM | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)April 2 at 7:57 AM | theglobeandmail.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025March 31, 2025 | globenewswire.comNanobiotix reports promising NSCLC treatment study resultsMarch 29, 2025 | investing.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest Down 68.6% in MarchNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 9,200 shares, a drop of 68.6% from the February 28th total of 29,300 shares. Based on an average trading volume of 20,100 shares, the short-interest ratio is currently 0.5 days. Approximately 0.0% of the shares of the company are short sold.March 28, 2025 | marketbeat.comNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCMarch 27, 2025 | globenewswire.comNanobiotix (NBTX) to Release Quarterly Earnings on MondayNanobiotix (NASDAQ:NBTX) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports.March 23, 2025 | marketbeat.comLeerink Partnrs Predicts Higher Earnings for NanobiotixNanobiotix S.A. (NASDAQ:NBTX - Free Report) - Research analysts at Leerink Partnrs raised their FY2024 EPS estimates for Nanobiotix in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.94) for the yMarch 22, 2025 | marketbeat.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer ConferenceMarch 20, 2025 | globenewswire.comNanobiotix amends global licensing agreement with Janssen PharmaceuticaMarch 18, 2025 | markets.businessinsider.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest Up 37.6% in FebruaryNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 29,300 shares, an increase of 37.6% from the February 13th total of 21,300 shares. Based on an average daily volume of 32,500 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.1% of the company's shares are sold short.March 17, 2025 | marketbeat.comNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026March 17, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Shares Up 6.7% - Here's WhyNanobiotix (NASDAQ:NBTX) Trading Up 6.7% - Should You Buy?March 13, 2025 | marketbeat.comNanobiotix files $200M mixed securities shelfMarch 7, 2025 | markets.businessinsider.comNanobiotix files to sell 5.62M ordinary shares for holdersMarch 7, 2025 | markets.businessinsider.comNanobiotix (NASDAQ:NBTX) Upgraded to Hold at UBS GroupUBS Group raised shares of Nanobiotix to a "hold" rating in a research note on Monday.February 19, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Stock Price Down 2% - Should You Sell?Nanobiotix (NASDAQ:NBTX) Trading Down 2% - Here's WhyFebruary 19, 2025 | marketbeat.comNanobiotix downgraded to Neutral from Buy at UBSFebruary 17, 2025 | markets.businessinsider.comUBS downgrades Nanobiotix (NBTX) to a HoldFebruary 17, 2025 | markets.businessinsider.com7 Best Nanotech Penny Stocks to Invest InFebruary 14, 2025 | insidermonkey.comIs Nanobiotix (NBTX) the Best Nanotech Penny Stock to Invest In?February 14, 2025 | insidermonkey.comNanobiotix to Participate in Multiple Investor Conferences in February and March 2025January 29, 2025 | globenewswire.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest Down 68.6% in JanuaryNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 22,300 shares, a decline of 68.6% from the December 31st total of 71,100 shares. Based on an average daily volume of 29,900 shares, the days-to-cover ratio is currently 0.7 days.January 28, 2025 | marketbeat.comNanobiotix doses first patient in CONVERGE studyJanuary 21, 2025 | markets.businessinsider.comNANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerJanuary 21, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Trading Down 6.8% - Here's What HappenedNanobiotix (NASDAQ:NBTX) Shares Down 6.8% - Time to Sell?December 20, 2024 | marketbeat.comNanobiotix to Unveil Future of NanotherapeuticsDecember 18, 2024 | markets.businessinsider.comNANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024December 17, 2024 | globenewswire.comNanobiotix S.A.: NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic CancerDecember 10, 2024 | finanznachrichten.deNANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic CancerDecember 9, 2024 | globenewswire.comNanobiotix (NASDAQ:NBTX) Trading Down 3.5% - Should You Sell?Nanobiotix (NASDAQ:NBTX) Shares Down 3.5% - Should You Sell?November 28, 2024 | marketbeat.comNanobiotix’s Market Influence and Innovation UnveiledNovember 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Nanobiotix: Promising Pipeline Progress and Strategic PartnershipsNovember 14, 2024 | markets.businessinsider.comNanobiotix Strengthens Growth and Financial ProspectsNovember 13, 2024 | markets.businessinsider.comNanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics PlatformsNovember 12, 2024 | finanznachrichten.deNANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics PlatformsNovember 12, 2024 | globenewswire.comNanobiotix (NASDAQ:NBTX) Trading Up 3.6% - Still a Buy?Nanobiotix (NASDAQ:NBTX) Stock Price Up 3.6% - What's Next?November 6, 2024 | marketbeat.comNANOBIOTIX to Participate in Multiple Investor Conferences in NovemberOctober 31, 2024 | globenewswire.comNanobiotix S.A. ADROctober 18, 2024 | wsj.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest UpdateNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 33,300 shares, a drop of 18.0% from the September 15th total of 40,600 shares. Based on an average daily trading volume, of 9,500 shares, the short-interest ratio is currently 3.5 days.October 13, 2024 | marketbeat.comNanobiotix S.A. (NASDAQ:NBTX) Sees Large Drop in Short InterestNanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 40,600 shares, a drop of 19.4% from the August 31st total of 50,400 shares. Based on an average daily volume of 9,600 shares, the short-interest ratio is presently 4.2 days.September 27, 2024 | marketbeat.comBuy Rating on Nanobiotix: Anticipating Key Data Readouts and Solid FinancialsSeptember 21, 2024 | markets.businessinsider.comNanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial ResultsSeptember 19, 2024 | finanznachrichten.deNANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial ResultsSeptember 18, 2024 | globenewswire.comNANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term GrowthSeptember 4, 2024 | globenewswire.comNanobiotix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comNanobiotix (NASDAQ:NBTX) Shares Up 8.5%Nanobiotix (NASDAQ:NBTX) Trading 8.5% HigherJuly 31, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading Up 1.2%Nanobiotix (NASDAQ:NBTX) Trading Up 1.2%July 6, 2024 | marketbeat.comNanobiotix (NASDAQ:NBTX) Stock Price Down 14%Nanobiotix (NASDAQ:NBTX) Trading Down 14%June 15, 2024 | marketbeat.com Remove Ads Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBTX Media Mentions By Week NBTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBTX News Sentiment▼0.580.61▲Average Medical News Sentiment NBTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBTX Articles This Week▼61▲NBTX Articles Average Week Remove Ads Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Today AbCellera Biologics News Today Arbutus Biopharma News Today ArriVent BioPharma News Today CureVac News Today ChromaDex News Today Trevi Therapeutics News Today Nuvation Bio News Today Bicycle Therapeutics News Today Immunome News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBTX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
